Vaccines against advanced melanoma

Clinics in Dermatology

Volumn 31, Issue 2, 2013, Pages 179-190

  Blanchard, Tatiana ^a   Srivastava, Pramod K ^a   Duan, Fei ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER TESTIS ANTIGEN; DENDRITIC CELL VACCINE; DIFFERENTIATION ANTIGEN; DNA VACCINE; DOPACHROME TAUTOMERASE; GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 96; GP100 [209-217]; GP100 [280-288]; HEAT SHOCK PROTEIN; INTERLEUKIN 2; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 10; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 4; MELANOMA VACCINE; MONOPHENOL MONOOXYGENASE; NY ESO 1 ANTIGEN; ONAMELATUCEL L; PEPTIDE VACCINE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TALIMOGENE LAHERPAREPVEC; TELOMERASE; TEMOZOLOMIDE; TUMOR ANTIGEN; TUMOR CELL VACCINE; TYROSINASE RELATED PROTEIN 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; DRUG MEGADOSE; GENE MUTATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LOW DRUG DOSE; MELANOMA SKIN CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TUMOR IMMUNOLOGY;

ANIMALS; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNOTHERAPY, ACTIVE; MELANOMA; MICE; SKIN NEOPLASMS;

EID: 84874229823     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2012.08.005     Document Type: Article

References (164)

1. Foley E.J. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res 1953, 13:835-837.
2. Prehn R.T., Main J.M. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957, 18:769-778.
3. Basombrio M.A. Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene. Cancer Res 1970, 30:2458-2462.
4. Klein G. The strange road to the tumor-specific transplantation antigens (TSTAs). Cancer Immun 2001, 1:6.
5. Hewitt H.B., Blake E.R., Walder A.S. A critique of the evidence for active host defense against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer 1976, 33:241-259.
6. Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 1974, 183:534-536.
7. Burnet M. Cancer-a biological approach.III. Viruses associated with neoplastic conditions. BMJ 1957, 1:841-846.
8. Thomas L. Cellular and humoral aspects of the hypersensitive states 1959, 529-532. Hoeber-Harper, New York. H.S. Lawrence (Ed.).
9. Boon T., Kellermann O. Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc Natl Acad Sci U S A 1977, 74:272-275.
10. Van Pel A., Georlette M., Boon T. Tumor cell variants obtained by mutagenesis of a Lewis lung carcinoma cell line: immune rejection by syngeneic mice. Proc Natl Acad Sci U S A 1979, 76:5282-5285.
11. Uyttenhove C., Van Snick J., Boon T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice. J Exp Med 1980, 152:1175-1183.
12. Van Pel A., Vessiere F., Boon T. Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis. J Exp Med 1983, 157:1992-2001.
13. Dighe A.S., Richards E., Old L.J., Schreiber R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFNγ receptors. Immunity 1994, 1:447-456.
14. Kaplan D.H., Shankaran V., Dighe A.S., et al. Demonstration of an interferon gamma -dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998, 95:7556-7561.
15. van den Broek M.E., Kagi D., Ossendorp F., et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med 1996, 184:1781-1790.
16. Smyth M.J., Thia K.Y.T., Street S.E.A., et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000, 191:661-668.
17. Shankaran V., Ikeda H., Bruce A.T., et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111.
18. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
19. Dye E.S., North R.J. T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases. J Exp Med 1981, 154:1033-1042.
20. North R.J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982, 155:1063-1074.
21. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
22. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
23. Young M.R., Newby M., Wepsic H.T. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic lewis lung carcinoma tumors. Cancer Res 1987, 47:100-105.
24. Sica A., Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007, 117:1155-1166.
25. Zheng P., Sarma S., Guo Y., Liu Y. Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: lessons from recurrent tumors. Cancer Res 1999, 59:3461-3467.
26. Seung S., Urban J.L., Schreiber H. A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target. J Exp Med 1993, 178:933-940.
27. Restifo N.P., Marincola F.M., Kawakami Y., Taubenberger J., Yannelli J.R., Rosenberg S.A. Loss of functional Beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996, 88:100-108.
28. de Vries T.J., Fourkour A., Wobbes T., Verkroost G., Ruiter D.J., van Muijen G.N.P. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res 1997, 57:3223-3229.
29. Sanchez-Perez L., Kottke T., Diaz R.M., et al. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res 2005, 65:2009-2017.
30. Dong H., Strome S.E., Salomao D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8:793-800.
31. Hahne M., Rimoldi D., Schroter M., et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996, 274:1363-1366.
32. Chappell D.B., Zaks T.Z., Rosenberg S.A., Restifo N.P. Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res 1999, 59:59-62.
33. Fingleton B., Carter K., Matrisian L. Loss of functional fas ligand enhances intestinal tumorigenesis in the min mouse model. Cancer Res 2007, 67:4800-4806.
34. Gorsch S.M., Memoli V.A., Stukel T.A., Gold L.I., Arrick B.A. Immunohistochemical staining for transforming growth factor 1 associates with disease progression in human breast cancer. Cancer Res 1992, 52:6949-6952.
35. Willimsky G., Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005, 437:141-146.
36. Khong H.T., Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002, 3:999-1005.
37. Huang M., Stolina M., Sharma S., et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998, 58:1208-1216.
38. Salazar-Onfray F., Lopez M.N., Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 2007, 18:171-182.
39. Almand B., Resser J.R., Lindman B., et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000, 6:1755-1766.
40. Saito H., Tsujitani S., Ikeguchi M., Maeta M., Kaibara N. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br J Cancer 1998, 78:1573-1577.
41. Pukel C.S., Lloyd K.O., Travassos L.R., Dippold W.G., Oettgen H.F., Old L.J. GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med 1982, 155:1133-1147.
42. Watanabe T., Pukel C.S., Takeyama H., et al. Human melanoma antigen AH is an autoantigenic ganglioside related to GD2. J Exp Med 1982, 156:1884-1889.
43. Natoli E.J., Livingston P.O., Pukel C.S., et al. A murine monoclonal antibody detecting N-acetyl- and N-glycolyl-GM2: Characterization of cell surface reactivity. Cancer Res 1986, 46:4116-4120.
44. Vijayasaradhi S., Bouchard B., Houghton A.N. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med 1990, 171:1375-1380.
45. Sahin U., Tureci O., Schmitt H., et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995, 92:11810-11813.
46. Houghton A.N. Cancer antigens: Immune recognition of self and altered self. J Exp Med 1994, 180:1-4.
47. Greenman C., Stephens P., Smith R., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
48. Sjoblom T., Jones S., Wood L.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
49. Bielas J.H., Loeb K.R., Rubin B.P., True L.D., Loeb L.A. From the cover: human cancers express a mutator phenotype. Proc Natl Acad Sci U S A 2006, 103:18238-18242.
50. Klein C.A. Random mutations, selected mutations: a PIN opens the door to new genetic landscapes. Proc Natl Acad Sci U S A 2006, 103:18033-18034.
51. Loeb L.A., Springgate C.F., Battula N. Errors in DNA replication as a basis of malignant changes. Cancer Res 1974, 34:2311-2321.
52. Loeb L.A., Loeb K.R., Anderson J.P. Multiple mutations and cancer. Proc Natl Acad Sci U S A 2003, 100:776-781.
53. Paulovich A.G., Toczyski D.P., Hartwell L.H. When Checkpoints Fail. Cell 1997, 88:315-321.
54. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
55. Mandelboim O., Berke G., Fridkin M., Feldman M., Eisenstein M., Eisenbach L. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 1994, 369:67-71.
56. Monach P.A., Meredith S.C., Siegel C.T., Schreiber H. A unique tumor antigen produced by a single amino acid substitution. Immunity 1995, 2:45-59.
57. Dubey P., Hendrickson R.C., Meredith S.C., et al. The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J Exp Med 1997, 185:695-706.
58. Lurquin C., Van Pel A., Mariame B., et al. Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 1989, 58:293-303.
59. Van der Bruggen P., Stroobant V., Van Pel A., Van den Eynde B. T-cell defined tumor antigens. Cancer Immun 2001, Available at:. http://cancerimmunity.org/peptide/mutations/.
60. Dubey P., Meredith S.C., Siegel C.T., Schreiber H. Tumor cells induce cytolytic T cells to a single immunodominant mutant peptide. J Immunother 1998, 21:277-282.
61. Dyall R., Bowne W.B., Weber L.W., et al. Heteroclitic immunization induces tumor immunity. J Exp Med 1998, 188:1553-1561.
62. Slansky J.E., Rattis F.M., Boyd L.F., et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 2000, 13:529-538.
63. Guevara-Patino J.A., Engelhorn M.E., Turk M.J., et al. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest 2006, 116:1382-1390.
64. Engelhorn M.E., Guevara-Patino J.A., et al. Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat Med 2006, 12:198-206.
65. Novellino L., Renkvist N., Rini F., et al. Identification of a mutated receptor-like protein tyrosine phosphatase κ as a novel, class II HLA-restricted melanoma antigen. J Immunol 2003, 170:6363-6370.
66. Echchakir H., Mami-Chouaib F., Vergnon I., et al. A point mutation in the α-Actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res 2001, 61:4078-4083.
67. Sharkey M.S., Lizee G., Gonzales M.I., Patel S., Topalian S.L. CD4+ T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Res 2004, 64:1595-1599.
68. Robbins P.F., El-Gamil M., Li Y.F., et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996, 183:1185-1192.
69. Lennerz V., Fatho M., Gentilini C., et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A 2005, 102:16013-16018.
70. Hogan K.T., Eisinger D.P., Cupp S.B., et al. The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. Cancer Res 1998, 58:5144-5150.
71. Wang H.Y., Zhou J., Zhu K., Riker A.I., Marincola F.M., Wang R.F. Identification of a mutated fibronectin as a tumor antigen recognized by CD4+T cells: its role in extracellular matrix formation and tumor metastasis. J Exp Med 2002, 195:1397-1406.
72. Brandle D., Brasseur F., Weynants P., Boon T., Van den Eynde B. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med 1996, 183:2501-2508.
73. Huang J., El-Gamil M., Dudley M.E., Li Y.F., Rosenberg S.A., Robbins P.F. T Cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class i gene product. J Immunol 2004, 172:6057-6064.
74. Gaudin C., Kremer F., Angevin E., Scott V., Triebel F. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. J Immunol 1999, 162:1730-1738.
75. Gueguen M., Patard J.J., Gaugler B., et al. An antigen recognized by autologous CTLs on a human bladder carcinoma. J Immunol 1998, 160:6188-6194.
76. Kawakami Y., Wang X., Shofuda T., et al. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. J Immunol 2001, 166:2871-2877.
77. Takenoyama M., Baurain J.F., Yasuda M., et al. A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma. Int J Cancer 2006, 118:1992-1997.
78. Vigneron N., Ooms A., Morel S., Degiovanni G., Van den Eynde B.J. Identification of a new peptide recognized by autologous cytolytic T lymphocytes on a human melanoma. Cancer Immun 2002, 19-29.
79. Sensi M., Nicolini G., Zanon M., et al. Immunogenicity without Immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8+ T cells with a memory phenotype. Cancer Res 2005, 65:632-640.
80. Gjertsen M.K., Bjørheim J., Saeterdal I., Myklebust J., Gaudernack G. Cytotoxic CD4+ and CD8+T lymphocytes, generated by mutant p21-ras(12VAL) peptide vaccination of a patient, recognize 12VAL-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Immunol 1997, 72:784-790.
81. Linard B., Bezieau S., Benlalam H., et al. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J Immunol 2002, 168:4802-4808.
82. Wolfel T., Hauer M., Schneider J., et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995, 269:1281-1284.
83. Chiari R., Foury F., De Plaen E., Baurain J.-F., Thonnard J.G., Coulie P. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. Cancer Res 1999, 59:5785-5792.
84. Karanikas V., Colau D., Baurain J.F., et al. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001, 61:3718-3724.
85. Zorn E., Hercend T. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol 1999, 29:592-601.
86. Pieper R., Christian R.E., Gonzales M.I., et al. Biochemical identification of a mutated human melanoma antigen recognized by CD4+ T cells. J Exp Med 1999, 189:757-766.
87. Maccalli C., Li Y.F., El-Gamil M., Rosenberg S.A., Robbins P.F. Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4+ T lymphocytes. Cancer Res 2003, 63:6735-6743.
88. Topalian S.L., Gonzales M.I., Ward Y., Wang X., Wang R.-F. Revelation of a cryptic major histocompatibility complex class II-restricted tumor epitope in a novel RNA-processing enzyme. Cancer Res 2002, 62:5505-5509.
89. Wang R.-F., Wang X., Atwood A.C., Topalian S.L., Rosenberg S.A. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 1999, 284:1351-1354.
90. Yotnda P., Firat H., Garcia-Pons F., et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998, 101:2290-2296.
91. Makita M., Azuma T., Hamaguchi H., et al. Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes. Leukemia 2002, 16:2400-2407.
92. Wang R.-F., Wang X., Rosenberg S.A. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4+ T cells. J Exp Med 1999, 189:1659-1668.
93. Gambacorti-Passerini C., Grignani F., Arienti F., Pandolfi P.P., Pelicci P.G., Parmiani G. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. Blood 1993, 81:1369-1375.
94. Yotnda P., Garcia F., Peuchmaur M., et al. Cytotoxic T cell RESPONSE AGAINST THE CHIMERIC ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J Clin Invest 1998, 102:455-462.
95. Yun C., Senju S., Fujita H., et al. Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein. Tissue Antigens 1999, 54:153-161.
96. Schwitalle Y., Linnebacher M., Ripberger E., Gebert J., von Knebel Doeberitz M. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. Cancer Immun 2004, 4:14.
97. Ripberger E., Linnebacher M., Schwitalle Y., Gebert J., Von Knebel Doeberitz M. Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT Gene. J Clin Immunol 2003, 23:415-423.
98. Mandruzzato S., Brasseur F., Andry G., Boon T., Bruggen P.V.D. A CASP-8 Mutation Recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 1997, 186:785-793.
99. Chen Y. Identification of human tumor antigens by serological expression cloning: an online review on SEREX. Cancer Immun 2004, Available at:. http://www.cancerimmunity.org/SEREX/.
100. van der Bruggen P., Traversari C., Chomez P., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
101. Gotter J., Brors B., Hergenhahn M., Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med 2004, 199:155-166.
102. Houghton A.N., Gold J.S., Blachere N.E. Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol 2001, 13:134-140.
103. Houghton A.N., Eisinger M., Albino A.P., Cairncross J.G., Old L.J. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med 1982, 156:1755-1766.
104. Brichard V., Van Pel A., Wolfel T., et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993, 178:489-495.
105. Bakker A.B., Schreurs M.W., de Boer A.J., et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes. J Exp Med 1994, 179:1005-1009.
106. Kawakami Y., Eliyahu S., Delgado C.H., et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A 1994, 91:6458-6462.
107. Coulie P.G., Brichard V., Van Pel A., et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994, 180:35-42.
108. Kawakami Y., Eliyahu S., Delgado C.H., et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 1994, 91:3515-3519.
109. Kawakami Y., Eliyahu S., Sakaguchi K., et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994, 180:347-352.
110. Wang R.F., Appella E., Kawakami Y., Kang X., Rosenberg S.A. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996, 184:2207-2216.
111. Nordlund J.J., Kirkwood J.M., Forget B.M., Milton G., Albert D.M., Lerner A.B. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983, 9:689-696.
112. Bystryn J.C., Riegel D., Friedman R.J., Friedman R.J. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 1987, 123:1053-1055.
113. Rosenberg S.A., White D.E. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 1996, 19:81-84.
114. Richards J.M., Mehta N., Ramming K., Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992, 10:1338-1343.
115. Chiari R., Hames G., Stroobant V., et al. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res 2000, 60:4855-4863.
116. Fisk B., Blevins T.L., Wharton J.T., Ioannides C.G. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995, 181:2109-2117.
117. Ikeda H., Lethe B., Lehmann F., et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997, 6:199-208.
118. Schmitz M., Diestelkoetter P., Weigle B., et al. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 2000, 60:4845-4849.
119. Vonderheide R.H., Hahn W.C., Schultze J.L., Nadler L.M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999, 10:673-679.
120. Zhang L., Conejo-Garcia J.R., Katsaros D., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213.
121. Galon J.R.M., Costes A., Sanchez-Cabo F., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
122. Mahmoud S.M.A., Paish E.C., Powe D.G., et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011, 29:1949-1955.
123. Haanen J., Baars A., Gomez R., et al. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother 2006, 55:451-458.
124. UpToDate. Helping clinicians provide the best patient care. http://www.uptodate.com/.
125. Coulie P.G., Karanikas V., Colau D., et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A 2001, 98:10290-10295.
126. Gold J.S., Ferrone C.R., Guevara-Patino J.A., et al. A single heteroclitic epitope determines cancer immunity after xenogeneic dna immunization against a tumor differentiation antigen. J Immunol 2003, 170:5188-5194.
127. Geluk A., van den Eeden S.J.F., Dijkman K., et al. ML1419c peptide immunization induces mycobacterium leprae-specific HLA-A*0201-restricted CTL in vivo with potential to kill live mycobacteria. J Immunol 2011, 187:1393-1402.
128. Castle J.C., Kreiter S., Diekmann J., et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012, 72:1081-1091.
129. Kast W.M., Remco M.P.B., Cornelis J.M. Strict peptide length is not required for the induction of cytotoxic T lymphocyte-mediated antiviral protection by peptide vaccination. Eur J Immunol 1993, 23:1189-1192.
130. Toes R.E., Blom R.J., Offringa R., Kast W.M., Melief C.J. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol 1996, 156:3911-3918.
131. Toes R.E., Offringa R., Blom R.J., Melief C.J., Kast W.M. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci U S A 1996, 93:7855-7860.
132. Gnjatic S., Jager E., Chen W., et al. CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc Natl Acad Sci U S A 2002, 99:11813-11818.
133. Schwartzentruber D.J., Lawson D.H., Richards J.M., et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011, 364:2119-2127.
134. Palucka A., Dhodapkar M., Paczesny S., et al. Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. J Immunother 2003, 26:432-439.
135. Ardavin C., Amigorena S., Reis e Sousa C. Dendritic cells: immunobiology and cancer immunotherapy. Immunity 2004, 20:17-23.
136. Schuler-Thurner B., Schultz E.S., Berger T.G., et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002, 195:1279-1288.
137. Steele J.C., Rao A., Marsden J.R., et al. Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma. Gene Ther 2011, 18:584-593.
138. Bedrosian I., Mick R., Xu S., et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol 2003, 21:3826-3835.
139. Bowne W.B., Srinivasan R., Wolchok J.D., et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 1999, 190:1717-1722.
140. Weber L.W., Bowne W.B., Wolchok J.D., et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 1998, 102:1258-1264.
141. Overwijk WW, Restifo NP. B16 as a mouse model for human melanoma. Curr Protoc Immunol 2001;Chapter 20:Unit 20.1.
142. Overwijk W.W., Lee D.S., Surman D.R., et al. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4+ T lymphocytes. Proc Natl Acad Sci U S A 1999, 96:2982-2987.
143. Molinari P., Crespo M.I., Gravisaco M.J., Taboga O., Moron G. Baculovirus capsid display potentiates OVA cytotoxic and innate immune responses. PLoS One 2011, 6:e24108.
144. Senzer N.N., Kaufman H.L., Amatruda T., et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009, 27:5763-5771.
145. Neller M.A., López J.A., Schmidt C.W. Antigens for cancer immunotherapy. Semin Immunol 2008, 20:286-295.
146. Hsueh E.C., Essner R., Foshag L.J., et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002, 20:4549-4554.
147. Morton D.L., Hsueh E.C., Essner R., et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 2002, 236:438-448.
148. Morton D.L., Mozzillo N., Thompson J.F., et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. Proc 2007 ASCO Annual Meeting [meeting abstracts from post-meeting edition]. J Clin Oncol 2007, 25(18 Suppl):8508.
149. Sondak V.K., Liu P.Y., Tuthill R.J., et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002, 20:2058-2066.
150. Copier J., Dalgleish A. Whole-cell vaccines: a failure or a success waiting to happen?. Curr Opin Mol Ther 2010, 12:14-20.
151. Peggs K.S., Quezada S.A., Chambers C.A., Korman A.J., Allison J.P. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009, 206:1717-1725.
152. Dranoff G., Jaffee E., Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993, 90:3539-3543.
153. Berd D., Sato T., Maguire H.C., Kairys J., Mastrangelo M.J. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004, 22:403-415.
154. Tamura Y., Peng P., Liu K., Daou M., Srivastava P.K. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997, 278:117-120.
155. Binder R.J., Srivastava P.K. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat Immunol 2005, 6:593-599.
156. Basu S., Binder R.J., Ramalingam T., Srivastava P.K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001, 14:303-313.
157. Testori A., Richards J., Whitman E., et al. Phase III comparison of Vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 Study Group. J Clin Oncol 2008, 26:955-962.
158. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
159. Robert C., Thomas L., Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
160. Srivastava P.K., Callahan M.K., Mauri M.M. Treating human cancers with heat shock protein-peptide complexes: the road ahead. Expert Opin Biol Ther 2009, 9:179-186.
161. Srivastava P.K., Old L.J. Individually distinct transplantation antigens of chemically induced mouse tumors. Immunol Today 1988, 9:78-83.
162. Srivastava P.K. Peptide-binding heat shock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation. Adv Cancer Res 1993, 62:153-177.
163. Srivastava N., Srivastava P.K. Modeling the repertoire of true tumor-specific MHC I epitopes in a human tumor. PLoS One 2009, 4:e6094.
164. Buckwalter M.R., Srivastava P.K. "It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer. Semin Immunol 2008, 20:296-300.